Login to Your Account



Earnings roundup


Tuesday, May 6, 2014
Auxilium Pharmaceuticals Inc., of Chesterbrook, Pa., reported first quarter earnings of $88.5 million, compared to $66.2 million for the first quarter of 2013, a 34 percent increase mainly due to the addition of revenues from the products acquired as part of the Actient Holdings LLC, of Lake Forest, Ill., acquisition in April 2013, as well as the launch of Stendra (avanafil) for erectile dysfunction and Xiaflex (collagenase clostridium histolyticum) for Peyronie's disease during the first quarter of 2014, and was partially offset by a decline in revenues from Testim (testosterone gel), which garnered U.S. net revenues of $10.9 million, down 76 percent compared to the same time period in 2013.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription